KCT0003833撤回未知
A single arm phase II trial to evaluate the efficacy of Poziotinib, pan HER inhibitor in recurrent/metastatic esophageal cancer
试验速览
- 阶段
- 未知
- 状态
- 撤回
- 入组人数
- 49
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 20(Year) 至 0No Limit（—）
- 性别
- All
入选标准
- •1. Histologically confirmed esophageal squamous cell carcinoma (includes cases with pathologic findings with clinical course comparable to squamous cell carcinoma. For example, undifferentiated carcinoma).
- •2. Diseases that can not achieve curative aim with radical surgery, radiation, or chemo-radiotherapy.
- •3. Previous palliative chemotherapy including platinum-based agents for advanced or recurrent esophageal squamous cell carcinoma (If the disease progresses within 6 months after the curative platinum-based chemotherapy or disease progresses within 6 months after last adjuvant chemotherapy, it is considered to be the previous palliative chemotherapy.
- •4. Have measurable disease based on RECIST(Response evaluation criteria in solid tumors) 1.1.
- •5. Age > 20 years at time of study entry.
- •6. Performance status of 0 or 1 on the Eastern Cooperative Oncology Group Performance Scale.
- •7. Demonstrate adequate organ function.
- •Absolute Neutrophil Count = 1500/µL
- •Platelet Count =100,000/µL
- •Hemoglobin = 9.0 g/dL
- •Serum creatinine = 1.5 x ULN (Upper limit of normal)
- •Serum bilirubin = 1.5 x ULN Upper limit of normal)
- •AST, ALT = 3.0 x ULN (Upper limit of normal) with liver metastasis = 5.0 x ULN(Upper limit of normal))
- •8. Be willing and able to provide written informed consent/assent for the trial.
- •9. Subjects who understand that they have the right to sign a written consent form prior to participation in the clinical trial or to withdraw consent form participation in the clinical trial without disadvantage at any time.
排除标准
- •1. Without measurable lesion based on RECIST(Response evaluation criteria in solid tumors) 1.1.
- •2. Has received prior therapy with EGFR/HER2(Epidermal growth factor receptor/human epidermal growth factor receptor 2) directed therapy.
- •3. Subjects who underwent major surgery requiring general anesthesia within 4 weeks before enrollment.
- •4. Has history of intestinal obstruction or recent bleeding (subjects with clinically significant hemorrhagic or clotting events within the past 6 months).
- •5. Pregnant or lactating women.
- •6. Women who have not received a baseline pregnancy test or have a positive result(A woman who has not undergone a previous hysterectomy, or history of amenorrhea of more than 12 months, or undergone bilateral oophorectomy is considered to be a non-pregnant menopausal woman).
- •7. Male or reproductive women who are not willing to use contraception during the trial.
- •8. Has a known additional malignancy that is progressing or requires active treatment within 3 years(Except skin basal cell carcinoma, cervix epithelial carcinoma in situ, Superficial bladder cancer).
- •9. Subjects who interfere with the understanding of the written consent or are likely to affect the compliance of the trial medication, patients with uncontrolled seizures, central nervous system disorders or psychiatric disorders that are considered clinically significant by the investigator.
- •10. Subjects who have stable LVEF of less than 50%.
- •11. Received organ transplants that require immunosuppressive therapy.
- •12. Subjects who have uncontrolled active infectious disease.
- •13. Subjects who have symptomatic central nerve system metastasis(Except in case of discontinuation of corticosteroids at least 2 weeks before clinical trials and radiologic and neurologically stable cases over 4 weeks).
- •14. Subjects who have existing interstitial lung disease.
- •15. Subjects with class III or IV heart failure by the New York Heart Association (NYHA) classification, subjects with uncontrolled hypertension, unstable angina or myocardial infarction within the last 6 months, subjects with poorly controlled cardiac arrhythmia, or subjects was judged to have clinically significant cardiovascular abnormalities by the investigator.
- •16. Incapability of oral ingestion and digestion.
研究者
相似试验
进行中（未招募）
1 期
Behandlung von Patienten mit einer Akuten Myeloischen Leukämie mit einer c-KIT oder FLT3-ITD Mutation in Verbindung mit einer t(8;21) Mutation mit Midostaurin zusätzlich zur Standard-ChemotherapiePatients with newly diagnosed c-KIT or FLT3-ITD mutated t(821) AMLMedDRA version: 21.1 Level: LLT Classification code 10060557 Term: Acute myelocytic leukemia System Organ Class: 100000004864EUCTR2011-002567-17-DETechnische Universität Dresden18
尚未招募
2 期
Biomarcer-2 :Biomarker informed optimal management of advanced RAS wild type colorectal cancerAdvanced RAS Wild type right sided Colorectal cancerCancer - Bowel - Back passage (rectum) or large bowel (colon)ACTRN12623000874617Australasian Gastrointestinal Trials Group29
已完成
2 期
A single arm phase II trial evaluating the activity of alectinib for the treatment of pretreated RET-rearranged advanced NSCLCNL-OMON46669European Thoracic Oncology Platform (ETOP)4
进行中（未招募）
1 期
A research study to evaluate the activity of alectinib for the Treatment of pretreated patients with advanced NSCLC that have confirmed RET-rearrangement.EUCTR2017-002063-17-NLETOP (European Thoracic Oncology Platform)44
进行中（未招募）
1 期
A research study to evaluate the activity of alectinib for the Treatment of pretreated patients with advanced NSCLC that have confirmed RET-rearrangement.EUCTR2017-002063-17-SIETOP (European Thoracic Oncology Platform)44